Department of Hematology and Blood Banking, Faculty of Medicine, Gonabad University of Medical Sciences, Gonabad, Iran.
Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
J Thromb Thrombolysis. 2024 Aug;57(6):1018-1030. doi: 10.1007/s11239-024-02971-6. Epub 2024 May 9.
COVID-19 has been associated with alterations in coagulation. Recent reports have shown that protein C and S activities are altered in COVID-19. This may affect the complications and outcome of the disease. However, their exact role in COVID-19 remains uncertain. The aim of the current study was therefore to analyze all papers in the literature on protein C and S activities in COVID-19. We searched three medical electronic databases. Of the 2442 papers, 28 studies were selected for the present meta-analysis. For the meta-analysis, means ± standard deviations with 95% confidence intervals (CI) for protein C and S activities were extracted. Pooled p values were calculated using STATA software. Protein C and S activities were significantly lower in COVID-19 patients than in healthy controls (pooled p values: 0.04 and 0.02, respectively). Similarly, protein C activities were considerably lower in nonsurviving patients (pooled p value = 0.00). There was no association between proteins C or S and thrombosis risk or ICU admission in COVID-19 patients (p value > 0.05). COVID-19 patients may exhibit lower activities of the C and S proteins, which might affect disease outcome; however, additional attention should be given when considering therapeutic strategies for these patients.
COVID-19 与凝血功能改变有关。最近的报告显示,COVID-19 患者的蛋白 C 和 S 活性发生改变。这可能会影响疾病的并发症和结局。然而,它们在 COVID-19 中的确切作用仍不确定。因此,本研究旨在分析 COVID-19 中关于蛋白 C 和 S 活性的所有文献。我们检索了三个医学电子数据库。在 2442 篇论文中,选择了 28 项研究进行本次荟萃分析。对于荟萃分析,使用 STATA 软件提取蛋白 C 和 S 活性的均值±标准差和 95%置信区间 (CI)。汇总的 p 值用 STATA 软件计算。COVID-19 患者的蛋白 C 和 S 活性明显低于健康对照组(汇总的 p 值分别为 0.04 和 0.02)。同样,非存活患者的蛋白 C 活性明显较低(汇总 p 值=0.00)。在 COVID-19 患者中,蛋白 C 或 S 与血栓形成风险或 ICU 入院之间没有关联(p 值>0.05)。COVID-19 患者可能表现出蛋白 C 和 S 活性降低,这可能会影响疾病结局;然而,在考虑这些患者的治疗策略时应格外注意。